glp-1 obesity drug news today september 15 2025 Alarming rise in weight loss overdoses GLP-1 Agonists: Using Semaglutide, Tirzepatide,

Semaglutide and tirzepatide do not directly cause muscle wasting

Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W, and Bernier M

The drugs may also cause severe allergic reactions including shortness of breath, red rash, hives, abdominal pain, difficulty swallowing, and chest tightness

Exenatide long-acting preparations were launched in the United States in 2012 and officially launched in 2018 with the approval of the National Medical Products Administration (NMPA)

E., Bossuyt, P

Patients also have the option to forego insurance and pay out-of-pocket for the medication